Barely Significant
← all excerpts

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.

Cancers (Basel) · 2020 · PMC7656302 · PMID 33092063

Europe PMCDOI
2
hedged sentences
0.0300
closest p · 0.6× alpha
0.0700
boldest claim

The sentences

clearly significantp = 0.03actually significant
The mean AUCs of each compound might be higher in responding tumors ( Figure 4 C) and clearly significant for the mean AUC of D1 rapamycin ( p = 0.03).

also in 480 other papers

a statistical trendp = 0.07so close (0.05 < p ≤ 0.1)
Figure 5 B shows a statistical trend between a lower ADC value and PR or SD patients ( p = 0.07).

also in 2,485 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.